The immunostimulatory potential of the cGAS-STING pathway makes it an attractive pharmacological target, since its activation in the tumor microenvironment (TME) can induce efficient cross-priming of tumor-specific antigens and facilitate the infiltration of effector T cells. Here, STING1 is linked to neoplasm.